Africa

Asia Pacific

Europe

Middle East

North America

Latin America / Caribbean

South America

test

AbbViePro Logo 2023
MENU
Log in
or
Register
Log in
or
Register

Prescribing information can be found at the bottom of this page

Retinal disease

OZURDEX® (dexamethasone intravitreal implant) is indicated for the treatment of adult patients with:

teaser1

Visual impairment due to diabetic macular edema (DME) who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy

Find out more
teaser2

Macular edema following either branch retinal vein occlusion (BRVO) or central retinal vein occlusion  (CRVO)

Content coming soon

Job Number ALL-OZU-220048. Date of Preparation March 2023

OZURDEX® PRESCRIBING INFORMATION
AbbViePro Logo 2023
AbbViePro Logo 2023
Our therapy areas
Immunology
Oncology
Neuroscience
Virology
Eye Care
Additional info
Privacy Notice
Terms of Use
Contact Us

Report Adverse Event (AE reporting requirements to be localized)

This website is for Healthcare Professionals only


Job Number ALL-OZU-220048. Date of Preparation March 2023. This website has been developed and funded by AbbVie Ltd.


© 2019 AbbVie Ltd. All rights reserved. Registered number: 08004972 England.

img
img
Our therapy areas
Immunology
Oncology
Neurology
Virology
Our therapy areas
Immunology
Oncology
Neurology
Virology
Additional info
Privacy Policy
Terms and Conditions
Manage Cookies
Contact Us
Additional info
Privacy Policy
Terms and Conditions
Manage Cookies
Contact Us
This website is intended for Healthcare Professionals

Unless otherwise specified, all product names appearing in this internet site are trademarks owned by or licensed to AbbVie Inc., its subsidiaries or affiliates. No use of any AbbVie trademark, trade name, or trade dress in this site may be made without the prior written authorization of AbbVie Inc., except to identify the product or services of the company.

This website is intended for Italy Healthcare Professionals

Unless otherwise specified, all product names appearing in this internet site are trademarks owned by or licensed to AbbVie Inc., its subsidiaries or affiliates. No use of any AbbVie trademark, trade name, or trade dress in this site may be made without the prior written authorization of AbbVie Inc., except to identify the product or services of the company.

Date of Preparation: December 2018  |   Approval code AT-ABBV-210058 Aug 21    |    Copyright © 2018 AbbVie Inc. North Chicago, Illinois, U.S.A.

Date of Preparation: December 2018 

Approval code AT-ABBV-210058 Aug 21

Copyright © 2018 AbbVie Inc. North Chicago, Illinois, U.S.A.